Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.295
-0.105 (-3.09%)
Apr 2, 2026, 3:14 PM EDT - Market open
Agenus Employees
Agenus had 81 employees as of December 31, 2025. The number of employees decreased by 235 or -74.37% compared to the previous year.
Employees
81
Change (1Y)
-235
Growth (1Y)
-74.37%
Revenue / Employee
$1,409,827
Profits / Employee
-$1,247
Market Cap
126.52M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 81 | -235 | -74.37% |
| Dec 31, 2024 | 316 | -73 | -18.77% |
| Dec 31, 2023 | 389 | -144 | -27.02% |
| Dec 31, 2022 | 533 | 92 | 20.86% |
| Dec 31, 2021 | 441 | 82 | 22.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Humacyte | 184 |
| Inovio Pharmaceuticals | 112 |
| PepGen | 56 |
| Equillium | 35 |
| Spero Therapeutics | 32 |
| AN2 Therapeutics | 21 |
| Black Diamond Therapeutics | 21 |
AGEN News
- 1 day ago - Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer - Business Wire
- 1 day ago - Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript - Seeking Alpha
- 6 days ago - Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access - Business Wire
- 15 days ago - Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer - Business Wire
- 17 days ago - Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized - Business Wire
- 23 days ago - Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - Business Wire
- 4 weeks ago - Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update - Business Wire
- 5 weeks ago - Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL - Business Wire